Tech Company Financing Transactions
DalCor Pharmaceuticals Funding Round
DalCor Pharmaceuticals closed a $80 million Series D financing round on 9/21/2023. Investors included Andes Growth, Caisse de dépôt et placement du Québec and CTI Life Sciences Fund.
Transaction Overview
Company Name
Announced On
9/21/2023
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
677 N. Washington Blvd. 32
Sarasota, FL 34236
USA
Sarasota, FL 34236
USA
Phone
Website
Email Address
Overview
DalCor is focused on providing precision medicine through identification of genetically distinct patient populations that derive clinical benefits. By integrating clinical, biologic and genetic insights, DalCor intends to deliver superior outcomes in clinical medicine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Fouzia Laghrissi-Thode
Chief Financial Officer
Michael Dixon
Chief Medical Officer
Donald Black
VP - Operations
Therese Heinonen
VP - Operations
Peter Schuepbach
Browse more venture capital transactions:
Prev: 9/21/2023: Rencore venture capital transaction
Next: 9/21/2023: Medeloop venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs